Literature DB >> 16946951

Treatment of patients with first-episode psychosis: two-year outcome data from the Danish National Schizophrenia Project.

Bent Rosenbaum1, Kristian Valbak, Susanne Harder, Per Knudsen, Anne Køster, Matilde Lajer, Anne Lindhardt, Gerda Winther, Lone Petersen, Per Jørgensen, Merete Nordentoft, Anne Helms Andreasen.   

Abstract

First episode psychosis interventions have been in focus in the last two decades in an attempt to improve the course and outcome of schizophrenic disorders. The Danish National Schizophrenia Project began in 1997 its intake of patients, aged 16-35, with a first psychotic episode of a schizophrenic spectrum disorder, diagnosed by ICD-10 (F20-29). The study was carried out as a prospective, longitudinal, multicentre investigation, encompassing 16 centres, spread all over the country. The sample consists of 562 patients consecutively diagnosed during two years. Patients were treated with "supportive psychodynamic psychotherapy as a supplement to treatment as usual", "integrated, assertive, psychosocial and educational treatment programme", or "treatment as usual". Data on symptoms and social function and sociodemographic data were obtained at inclusion, and at year 1 and 2. The three sub-cohorts did not differ at baseline. After one year, the total sample of patients improved significantly concerning symptoms and social function. The significance of the improvement remained after two years. After one year, patients in the two intervention groups improved more concerning symptoms and social function than patients in the treatment-as-usual group. Improvement in the intervention groups continued into the second year. Patients receiving integrated assertive treatment faired better than those being treated with the less intensive method of supportive psychodynamic psychotherapy, and the latter group improved more than the treatment-as-usual group.

Entities:  

Year:  2006        PMID: 16946951      PMCID: PMC1525136     

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  17 in total

1.  Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications.

Authors:  D Linszen; P Dingemans; M Lenior
Journal:  Schizophr Res       Date:  2001-08-01       Impact factor: 4.939

2.  A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness.

Authors:  Lone Petersen; Pia Jeppesen; Anne Thorup; Maj-Britt Abel; Johan Øhlenschlaeger; Torben Østergaard Christensen; Gertrud Krarup; Per Jørgensen; Merete Nordentoft
Journal:  BMJ       Date:  2005-09-02

3.  Cognitively oriented psychotherapy for early psychosis (COPE): a 1-year follow-up.

Authors:  H Jackson; P McGorry; L Henry; J Edwards; C Hulbert; S Harrigan; P Dudgeon; S Francey; D Maude; J Cocks; P Power
Journal:  Br J Clin Psychol       Date:  2001-03

Review 4.  Neuroleptics and the natural course of schizophrenia.

Authors:  R J Wyatt
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

5.  Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors.

Authors:  J S Strauss; W T Carpenter
Journal:  Arch Gen Psychiatry       Date:  1977-02

6.  The Danish National Schizophrenia Project: prospective, comparative longitudinal treatment study of first-episode psychosis.

Authors:  Bent Rosenbaum; Kristian Valbak; Susanne Harder; Per Knudsen; Anne Køster; Matilde Lajer; Anne Lindhardt; Gerda Winther; Lone Petersen; Per Jørgensen; Merete Nordentoft; Anne Helms Andreasen
Journal:  Br J Psychiatry       Date:  2005-05       Impact factor: 9.319

7.  Early detection and intervention for initial episodes of schizophrenia.

Authors:  I R Falloon; R R Kydd; J H Coverdale; T M Laidlaw
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

8.  Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed?

Authors:  V Lehtinen; J Aaltonen; T Koffert; V Räkköläinen; E Syvälahti
Journal:  Eur Psychiatry       Date:  2000-08       Impact factor: 5.361

9.  Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group.

Authors:  R A Emsley
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

10.  Multiple-family groups and psychoeducation in the treatment of schizophrenia.

Authors:  W R McFarlane; E Lukens; B Link; R Dushay; S A Deakins; M Newmark; E J Dunne; B Horen; J Toran
Journal:  Arch Gen Psychiatry       Date:  1995-08
View more
  6 in total

1.  Psychometric evaluation of the Danish and Swedish Satisfaction with Life Scale in first episode psychosis patients.

Authors:  Jacek Hochwälder; Maria Mattsson; Ragnhild Holmqvist; Johan Cullberg; Bent Rosenbaum
Journal:  Qual Life Res       Date:  2012-05-15       Impact factor: 4.147

2.  Prevention of the first episode of psychosis.

Authors:  William R McFarlane
Journal:  Psychiatr Clin North Am       Date:  2010-12-18

Review 3.  Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions.

Authors:  Ori Elis; Janelle M Caponigro; Ann M Kring
Journal:  Clin Psychol Rev       Date:  2013-07-16

4.  Early intervention in psychosis: concepts, evidence and future directions.

Authors:  Patrick D McGorry; Eóin Killackey; Alison Yung
Journal:  World Psychiatry       Date:  2008-10       Impact factor: 49.548

5.  Mentalization-based treatment for psychotic disorder: protocol of a randomized controlled trial.

Authors:  Jonas Weijers; Coriene Ten Kate; Elisabeth Eurelings-Bontekoe; Wolfgang Viechtbauer; Rutger Rampaart; Anthony Bateman; Jean-Paul Selten
Journal:  BMC Psychiatry       Date:  2016-06-08       Impact factor: 3.630

6.  Baseline brain structural and functional predictors of clinical outcome in the early course of schizophrenia.

Authors:  Gaelle E Doucet; Dominik A Moser; Maxwell J Luber; Evan Leibu; Sophia Frangou
Journal:  Mol Psychiatry       Date:  2018-10-03       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.